Skip to main content

Advertisement

Figure 2 | Cardiovascular Diabetology

Figure 2

From: Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Figure 2

Meta-analysis of all available 4 randomized control trials with bezafibrate [[20, 21, 35, 36]] in “overall populations” (4946 patients), based in part on the comprehensive meta-analysis of Jun and colleagues [[37]]: 28% coronary events risk reduction was observed (relative risk 0.722, confidence interval 0.518-1.005). This effect was significantly augmented (shown below the bold white line) in the subgroups of appropriate patients with metabolic syndrome and dyslipidemia [19, 20].

Back to article page